Advanced search
Start date
Betweenand


Acute lymphoblastic leukemia animal model development: leukemia progression monitoring by ELISA

Full text
Author(s):
Mateus Milani
Total Authors: 1
Document type: Master's Dissertation
Press: Campinas, SP.
Institution: Universidade Estadual de Campinas (UNICAMP). Instituto de Biologia
Defense date:
Examining board members:
José Andrés Yunes; João Ernesto de Carvalho; Mônica Barbosa de Melo
Advisor: José Andrés Yunes
Abstract

Acute lymphoblastic leukemia (ALL) is the most common type of childhood cancer . The transplantation of human primary ALL cells in immunodeficient mice has been of much importance for understanding the disease's pathophysiology and testing new drugs. Unlike animal models of solid tumors whose volume is easily measured on the animal surface, the ALL infiltrates organs that are inaccessible to external antigens, hence the need to define more suitable methods for monitoring the disease's progression. Results presented here indicate that proteins secreted by the ALL can serve as quantitative markers of leukemic burden and are easily measured by ELISA of blood plasma samples. Among three tested proteins (B2M, IGFBP2 and Hsp90), Hsp90 ELISA analysis showed higher sensitivity than the analysis of leukemic cells on animal blood by flow cytometry of anti- huCD45 labeled cells. The levels of Hsp90 in human blood plasma were shown to be positively correlated with the percentage of leukemic cells in the bone marrow and liver and to a lesser extent with the levels in the spleen and peripheral blood (PB) over time, both in B-lineage ALL as in ALL-T. The Hsp90 ELISA allows the leukemia's engraftment detection in transplanted animals up to two weeks prior to detection by the traditional method of peripheral blood analysis by flow cytometry. Unlike observed for IGFBP2, treatment of leukemic animals with Dexamethasone or PI3K inhibitors did not interfere in Hsp90 levels, which remained proportional to the percentage of huCD45+ leukemic cells in the peripheral blood. Taken together, the results demonstrate that the analysis of animal plasma by Hsp90 ELISA is a better method than those currently used for early diagnosis and monitoring of human ALL on minimal residual disease levels, when the percentage of ALL cells is less than 5 % of the total bone marrow cells (AU)

FAPESP's process: 11/01725-3 - Development of an animal model for acute lymphoblastic leukemia: leukemia progression monitoring by ELISA
Grantee:Mateus Milani
Support Opportunities: Scholarships in Brazil - Master